NEWS
Discover recent news, press, publications & congress and industry news below.

For access to a press kit, please contact a member of the media team at info@anthostherapeutics.com.
Addressing Suboptimal Anticoagulation in Atrial Fibrillation
Nov 17, 2023 | PUBLICATIONS & CONGRESS
MODERATOR Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine Professor of Medicine Harvard Medical School Boston, Massachusetts, United States FACULTY FACULTY Jeffrey l. Weitz, MD,...
Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation
Nov 12, 2023 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics → November 12, 2023 08:15 ET Secondary Endpoints Also Showed a Highly Significant 74% Reduction in Major Bleeding and a 93% Reduction in Gastrointestinal (GI) Bleeding with Abelacimab These Results Triggered the Data Monitoring...
Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions
Sep 26, 2023 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics September 26, 2023 07:00 ET Study Participants May Transition from the Rivaroxaban Arm to Abelacimab in an Extension Study CAMBRIDGE, Mass., September 26, 2023 (BUSINESS WIRE) – Anthos Therapeutics, Inc., a clinical stage...
Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)
Sep 18, 2023 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics September 18, 2023 06:00 ET Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-to-Head Study Comparing a Factor XI Inhibitor to a DOAC Abelacimab...
Improving the Effectiveness of Anticoagulant Therapy: The Promise of Factor XI Inhibition
Sep 15, 2023 | PUBLICATIONS & CONGRESS
This CME-accredited symposium took place on 25th June 2023, as part of the International Society for Thrombosis and Haemostasis (ISTH) Congress in Montréal, Canada Chairpeople: Shaun G. Goodman Speakers: Jean M. Connors,3-5...
Abelacimab: Mechanism of Action (MoA)
Jun 29, 2023 | VIDEO
ISTH 2023 Oral Presentation: Patient-Relevant Bleeding Events Among Patients Taking Anticoagulant Medication
Jun 28, 2023 | PUBLICATIONS & CONGRESS
Presenting author: Dan Bloomfield, MD Co-authors: B Alexander Yi, Karen Lipworth, Steve Burrows, Mellanie True Hills, Tarin Patrikis, Karen Pieper, Marc P. Bonaca, John Glasspool Anthos Therapeutics, Inc.; Insocius; StopAfib.org, American Foundation for Women's...
Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
Jun 26, 2023 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics June 26, 2023, 02:00 ET Patient-Centric Survey Conducted in Collaboration with StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology, Capturing...
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
Jun 8, 2023 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics June 08, 2023 11:10 ET Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
May 9, 2023 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics May 09, 2023 09:45 ET Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient Issues to the...
Anthos Therapeutics to Present Four Posters at ISPOR 2023
May 5, 2023 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics May 05, 2023 08:00 ET Additional presentation spotlights GARDENIA registry design in patients with atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer Associated...
Dr. Ruff – LILAC-TIMI 76 Clinical Trial
Apr 27, 2023 | VIDEO
Evaluating Evolving Approaches to Treating Thrombosis in Cancer
Feb 9, 2023 | PUBLICATIONS & CONGRESS
MODERATOR Jean M. Connors, MD Medical Director, Hemostatic Antithrombotic Stewardship Medical Director, Anticoagulation Management Services (Hematology Division) Brigham and Women's Hospital/Dana-Farber Cancer Institute Associate Professor of Medicine...
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
Jan 3, 2023 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jan 3, 2023, 08:00 ET FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3 study with...
Management of Thrombosis in High-Risk Patients: Focus on Cancer Associated Thrombosis
Nov 2, 2022 | PUBLICATIONS & CONGRESS
This symposium took place on 11th July 2022, as part of the International Society on Thrombosis and Haemostasis (ISTH) Congress in London, UK Chairpeople: Ajay Kakkar,1 Gary Raskob2 Speakers: Mari Thomas,3 Paula Bolton-Maggs,4,5 Giancarlo Agnelli6,7...
Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Sep 8, 2022 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics Sept 08, 2022, 08:00 ET This is the second Fast Track designation issued by the FDA for abelacimab Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor XIa with high...
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab
Aug 25, 2022 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics -> Aug 25, 2022, 08:00 ET Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The MAGNOLIA study will compare abelacimab against the current standard of care for VTE in cancer associated...
Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab
Jul 13, 2022 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jul 11, 2022, 02:00 ET Additional Pharmacodynamic Data on Abelacimab Released at the 2022 Congress of the International Society on Thrombosis and Haemostasis (ISTH) CAMBRIDGE, Mass., July 13, 2022 /PRNewswire/ -- Anthos...
Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Jul 11, 2022 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jul 11, 2022, 02:00 ET Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high af nity and selectivity Earlier this year abelacimab became the rst-ever Factor XI inhibitor to...
Anthos Therapeutics Appoints Drew Young as Chief Commercial Officer and Head of Patient Experience
May 26, 2022 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics May 26, 2022, 08:00 ET CAMBRIDGE, Mass., May 26, 2022 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the...
Biotech 2050 Podcast with CEO John Glasspool
May 19, 2022 | MEDIA
Anthos Therapeutics to Host Discussion with Global Experts on the Promise of Factor XI Inhibition at the 2022 BIO International Convention
May 13, 2022 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jun 13, 2022, 08:00 ET CAMBRIDGE, Mass., June 13, 2022 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced that it...
Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial
May 5, 2022 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics May 05, 2022, 14:28 ET Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high af nity and selectivity Robust phase 3 clinical program includes two complementary trials...
Empowered Patient Podcast with CEO John Glasspool
Apr 19, 2022 | MEDIA
The Bio Report Podcast with CEO John Glasspool
Apr 14, 2022 | MEDIA
NPR Tech Nation Radio with CMO Dan Bloomfield, MD, FACC, FAHA
Mar 31, 2022 | MEDIA
Health Professional Radio with CEO John Glasspool
Mar 23, 2022 | MEDIA
BioTech IQ Podcast with CEO John Glasspool
Feb 11, 2022 | MEDIA
Business of Biotech Podcast with CEO John Glasspool
Feb 1, 2022 | MEDIA
BioSpace – Biopharma Executive Perspectives on 2022
Jan 10, 2022 | MEDIA
Anthos Therapeutics Appoints David McIntyre as Chief Financial Officer
Jan 5, 2022 | NEWS RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jan 05, 2022, 08:00 ET CAMBRIDGE, Mass., Jan. 5, 2022 /PRNewswire/ -- Anthos Therapeutics, a late-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the...
Factor XI Inhibition: The Holy Grail of Hemostasis‐ Sparing Anticoagulation
Dec 9, 2021 | PUBLICATIONS & CONGRESS
Atrial Fibrillation Clinical Trial with Novel Dual Activity Factor XI Agent Completes Enrollment
Dec 7, 2021 | NEWS RELEASES
Atrial Fibrillation Clinical Trial with Novel Dual Activity Factor XI Agent Completes Enrollment NEWS PROVIDED BY Anthos Therapeutics Dec 07, 2021, 08:00 ET CAMBRIDGE, Mass., Dec. 7, 2021 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biopharma company...
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis – JACC 2021
Sep 3, 2021 | PUBLICATIONS & CONGRESS
Abelacimab for prevention of thromboembolism – NEJM 2021
Jul 19, 2021 | PUBLICATIONS & CONGRESS
Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine
Jul 19, 2021 | NEWS RELEASES
Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine Abelacimab achieved a ~80% reduction in venous...
Anthos: Solving the thrombosis dilemma with a hemostasis-sparing anticoagulant
Jul 7, 2021 | PUBLICATIONS & CONGRESS
Anthos is developing a pioneering phase 2 monoclonal antibody, abelacimab, as an effective anticoagulant that aims to provide treatment by inhibiting Factor XI to avoid severe bleeding. Thrombosis is a major unmet need. Globally more than one in four people die from...
Advantages and Disadvantages of Novel Oral Anticoagulants
Jul 6, 2021 | INDUSTRY NEWS
Thromboembolism prophylaxis in orthopaedics: an update
Jul 6, 2021 | INDUSTRY NEWS
Safety of new oral anticoagulant drugs: a perspective
Jul 6, 2021 | INDUSTRY NEWS
MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood 2019
Jul 6, 2021 | PUBLICATIONS & CONGRESS
Blackstone Life Sciences and Novartis Create Anthos Therapeutics to Develop Innovative Targeted Medicines for Cardiovascular Disease
Jul 6, 2021 | INDUSTRY NEWS
Blackstone Life Sciences Leads $250M Financing Blackstone Life Sciences and Novartis today announced the launch of Anthos Therapeutics Inc. (“Anthos”), a new biopharmaceutical company focused on advancing next generation targeted therapies for high-risk cardiovascular...
Anthos Therapeutics dubbed one of the fiercest biotech companies in the world
Jul 6, 2021 | MEDIA
Anthos Therapeutics is Developing a Hemostasis-Sparing Anticoagulant to Reduce the Hazard of Bleeding
Jul 6, 2021 | MEDIA
Big Bets on Biotech – Healthy Returns Summit with Nicholas Galakatos
Jul 5, 2021 | INDUSTRY NEWS